The testosterone replacement therapy for prostate cancer patients: Time to take the leap?

Area of Science:

• Oncology
• Endocrinology
• Urology

Background:

• Systemic therapies have reduced prostate cancer (PCa) mortality but increased long-term treatment-induced hypogonadism.
• Testosterone replacement therapy (TRT) is known to improve erectile function and cardiovascular health in men without PCa.

Purpose of the Study:

• To review the safety and efficacy of TRT in men treated for prostate cancer.
• To identify the optimal patient population eligible for TRT after PCa treatment.

Main Methods:

• Literature review of studies investigating TRT in PCa patients.
• Analysis of existing data on TRT's effects on PCa outcomes and patient well-being.

Main Results:

• TRT has shown potential benefits in improving quality of life for hypogonadal men.
• The safety and efficacy of TRT in PCa patients require careful consideration and further investigation.

Conclusions:

• TRT may be a viable option for select prostate cancer survivors experiencing hypogonadism.
• Defining the ideal candidates for TRT post-PCa treatment is crucial for maximizing benefits and minimizing risks.